Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N H Gordon

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cancer|November 1, 1989
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancerO H Pearson, C A Hubay, N H Gordon, et al.
Surgery|October 1, 1987
Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapyJ P Crowe, N H Gordon, A R Antunez, et al.
Clinical Orthopaedics and Related Research|July 1, 1985
The long-term fate of fresh and frozen orthotopic bone allografts in genetically defined ratsG D Bos, V M Goldberg, N H Gordon, et al.
Cancer Research|November 14, 1997
O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNUW P Phillips, J K Willson, S D Markowitz, et al.
Surgery, Gynecology & Obstetrics|October 11, 1991
Estrogen receptor determination and long term survival of patients with carcinoma of the breastJ P Crowe, N H Gordon, C A Hubay, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2001
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancerA Dowlati, N Levitan, N H Gordon, et al.
Lancet (London, England)|April 20, 1996
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalR D Gelber, B F Cole, A Goldhirsch, et al.
Surgery|October 1, 1990
Short-term tamoxifen plus chemotherapy: superior results in node-positive breast cancerJ P Crowe, N H Gordon, R R Shenk, et al.
Breast Cancer Research and Treatment|January 1, 1983
Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year resultsO H Pearson, C A Hubay, J S Marshall, et al.
Current Surgery|January 1, 1984
The prognostic importance of estrogen receptor level for Stage I breast cancer patientsJ P Crowe, N H Gordon, C A Hubay, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancer|November 1, 1989
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancerO H Pearson, C A Hubay, N H Gordon, et al.
Surgery|October 1, 1987
Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapyJ P Crowe, N H Gordon, A R Antunez, et al.
Clinical Orthopaedics and Related Research|July 1, 1985
The long-term fate of fresh and frozen orthotopic bone allografts in genetically defined ratsG D Bos, V M Goldberg, N H Gordon, et al.
Cancer Research|November 14, 1997
O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNUW P Phillips, J K Willson, S D Markowitz, et al.
Surgery, Gynecology & Obstetrics|October 11, 1991
Estrogen receptor determination and long term survival of patients with carcinoma of the breastJ P Crowe, N H Gordon, C A Hubay, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2001
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancerA Dowlati, N Levitan, N H Gordon, et al.
Lancet (London, England)|April 20, 1996
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalR D Gelber, B F Cole, A Goldhirsch, et al.
Surgery|October 1, 1990
Short-term tamoxifen plus chemotherapy: superior results in node-positive breast cancerJ P Crowe, N H Gordon, R R Shenk, et al.
Breast Cancer Research and Treatment|January 1, 1983
Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year resultsO H Pearson, C A Hubay, J S Marshall, et al.
Current Surgery|January 1, 1984
The prognostic importance of estrogen receptor level for Stage I breast cancer patientsJ P Crowe, N H Gordon, C A Hubay, et al.
Pageof 6